<DOC>
	<DOCNO>NCT00298428</DOCNO>
	<brief_summary>The risk thrombotic complication implantation drug-eluting stent ( DES ) may increase patient diabetes mellitus ( DM ) metabolic syndrome ( MS ) . It recommend patient take association aspirin clopidogrel several month DES implantation reduce risk . However , biological efficacy current antiplatelet therapy study prospectively specifically DM MS patient . Our aim study biological efficacy association aspirin clopidogrel ( 600 mg load dose follow 75 mg maintenance dose ) use assay measure ex vivo shear-induced platelet aggregation ( SIPA ) , along assay measure platelet activation aggregation , patient DM , MS , DM/MS . Patients stable coronary artery disease successful DES implantation native coronary artery eligible . They stratify entry accord metabolic status ( DM , MS , DM/MS ) . Measurements perform 6-24 hour clopidogrel load dose ( acute effect ) 4 month later clopidogrel maintenance dose ( chronic effect ) . Study end-points : A . Primary biological end-point : To compare SIPA level DM vs. MS vs. DM/MS patient . B . Secondary biological end-points : - To compare result test platelet aggregation/activation DM vs. MS vs. DM/MS patient . - To compare acute ( 6-24 hour clopidogrel load dose ) chronic ( 4 month later ) result mention test . These comparison perform overall population group ( DM , MS , DM/MS ) . C. Secondary clinical end-points : To study relationship SIPA level ( test platelet aggregation/activation ) occurrence : - Periprocedural myocardial infarction - Major adverse cardiac event ( cardiovascular death , myocardial infarction ischaemia-driven target vessel revascularization ) 4 12 month stent implantation . We , researcher Assistance PUBLIQUE - HOPITAUX de Paris , anticipate study may help improve knowledge efficacy current antiplatelet therapy DM MS patient treat DES .</brief_summary>
	<brief_title>Biological Efficacy Clopidogrel After Implantation Drug-eluting Stents ( SPACE )</brief_title>
	<detailed_description>The risk thrombotic complication implantation drug-eluting stent ( DES ) coronary artery may increase patient diabetes mellitus ( DM ) metabolic syndrome ( MS ) . It recommend patient take association aspirin clopidogrel several month DES implantation reduce risk . However , biological efficacy current antiplatelet therapy study prospectively specifically DM MS patient . In present study , study biological efficacy association aspirin clopidogrel ( 600 mg load dose follow 75 mg maintenance dose ) use assay measure ex vivo shear-induced platelet aggregation ( SIPA ) , along assay measure platelet activation aggregation , order well describe heterogeneity response antiplatelet agent patient DM , MS DM/MS . All patient stable coronary artery disease successful DES implantation native coronary artery ( include high risk feature , eg , leave main stenosis , bifurcation in-stent restenosis ) eligible . They stratify entry accord metabolic status ( DM , MS , DM/MS ) . Measurements perform 6-24 hour clopidogrel load dose ( acute effect ) 4 month later clopidogrel maintenance dose ( chronic effect ) . Study end-points : A . Primary biological end-point : To compare SIPA level DM vs. MS vs. DM/MS patient . B . Secondary biological end-points : - To compare result test platelet aggregation/activation ( light transmittance aggregometry response ADP arachidonic acid ; flow cytometry measurement VASP phosphorylation , platelet expression P-selectin GPIIbIIIa , circulate level platelet microparticles leukocyte-platelet aggregate ; PFA-100 occlusion time ; circulate level thromboxane B2 ) circulating level marker atherosclerosis ( CRPhs , von Willebrand factor , PAI-1 , fibrinogen , soluble CD40L ) DM vs. MS vs. DM/MS patient . - To compare acute ( 6-24 hour clopidogrel load dose ) chronic ( 4 month later ) result mention test . These comparison perform overall population group ( DM , MS , DM/MS ) . C. Secondary clinical end-points : To study relationship SIPA level ( test platelet aggregation/activation ) occurrence : - Periprocedural myocardial infarction - Major adverse cardiac event ( cardiovascular death , myocardial infarction ischaemia-driven target vessel revascularization ) 4 12 month stent implantation . We anticipate study may help improve knowledge efficacy current antiplatelet therapy DM MS patient treat DES .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Age ≥18 year Documented myocardial ischaemia ( stable angina positive stress ECG stress myocardial scintigraphy , silent ischemia positive stress ECG stress myocardial scintigraphy , nonST elevation acute coronary syndrome ) Treatment least 100 mg/day aspirin ≥ 6 hour percutaneous coronary intervention 600 mg clopidogrel loadingdose give ≥ 6 hour &lt; 24 hour coronary angiography Presence one several stenosis native coronary artery require percutaneous coronary intervention implantation one several drugeluting stent STelevation acute coronary syndrome Pregnancy breast feeding Severe disease life expectancy lower 1 year High bleeding risk ( blood coagulation disorder , uncontrolled severe hypertension , active bleeding , history severe bleeding ) Intolerance contraindication aspirin clopidogrel Current treatment ( stop &lt; 10 day ) vitamin K antagonist Current treatment ( stop &lt; 10 day ) clopidogrel ( except clopidogrel loadingdose give prior percutaneous coronary intervention ) , ticlopidine , dipyridamole , nonsteroidal antiinflammatory agent , GPIIBIIIA blocker Oneyear followup impossible Refusal sign information consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>stent</keyword>
	<keyword>percutaneous coronary intervention</keyword>
	<keyword>platelet aggregation</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>shear</keyword>
	<keyword>metabolic syndrome</keyword>
</DOC>